IN2015DN00334A - - Google Patents

Download PDF

Info

Publication number: IN2015DN00334A
Authority: IN; India
Prior art keywords: disorders; diseases; compounds; formula; methods
Prior art date: 2012-06-18

Application number

Other languages

English (en)

Inventor

Amy Allan

Bryan Branstetter

Brian Dyck

Michael I Weinhouse

Laurent Gomez

Tami Jo Marrone

Marco Peters

Original Assignee

Dart Neuroscience Cayman Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-18

Filing date

2013-06-18

Publication date

2015-06-12

2013-06-18 Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd

2015-06-12 Publication of IN2015DN00334A publication Critical patent/IN2015DN00334A/en

Links

230000015572 biosynthetic process Effects 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
150000005829 chemical entities Chemical class 0.000 abstract 1
230000007278 cognition impairment Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

IN334DEN2015 2012-06-18 2013-06-18 IN2015DN00334A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261661091P	2012-06-18	2012-06-18
PCT/US2013/046415 WO2013192229A1 (fr)	2012-06-18	2013-06-18	Composés pyridine azolopyrimidin-5-(6h)-ones substitués

Publications (1)

Publication Number	Publication Date
IN2015DN00334A true IN2015DN00334A (fr)	2015-06-12

Family

ID=49756458

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IN334DEN2015 IN2015DN00334A (fr)	2012-06-18	2013-06-18
IN335DEN2015 IN2015DN00335A (fr)	2012-06-18	2013-06-18

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IN335DEN2015 IN2015DN00335A (fr)	2012-06-18	2013-06-18

Country Status (17)

Country	Link
US (7)	US9284335B2 (fr)
EP (3)	EP3489238B8 (fr)
JP (2)	JP6129960B2 (fr)
KR (2)	KR102191816B1 (fr)
CN (2)	CN104583217B (fr)
AU (3)	AU2013277298B2 (fr)
BR (2)	BR112014031731B1 (fr)
CA (2)	CA2877146C (fr)
DK (2)	DK3489238T3 (fr)
ES (2)	ES2715325T3 (fr)
IL (2)	IL236233A (fr)
IN (2)	IN2015DN00334A (fr)
MX (2)	MX357320B (fr)
NZ (2)	NZ703950A (fr)
RU (2)	RU2659779C2 (fr)
SG (3)	SG11201408395WA (fr)
WO (2)	WO2013192229A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7947731B2 (en) *	2000-08-10	2011-05-24	Cold Spring Harbor Laboratory	Augmented cognitive training
RU2659779C2 (ru)	2012-06-18	2018-07-04	Дарт Нейросайенс (Кайман) Лтд	Замещенные соединения тиофен- и фуран-конденсированного азолопиримидин-5-(6н)-она
JP6396229B2 (ja) *	2014-01-27	2018-09-26	株式会社ポーラファルマ	使用時泡状を呈する外用医薬組成物
JP6396230B2 (ja) *	2014-01-27	2018-09-26	株式会社ポーラファルマ	使用時泡状を呈する外用医薬組成物
JP6396231B2 (ja) *	2014-01-27	2018-09-26	株式会社ポーラファルマ	使用時泡状を呈する外用医薬組成物
GB201406486D0 (en) *	2014-04-10	2014-05-28	Redx Pharma Ltd	Antibacterial compounds
TW201629064A (zh)	2014-10-10	2016-08-16	Ｈ朗德貝克公司	作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar)	2015-04-30	2020-08-27	H Lundbeck As	إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017046603A1 (fr) *	2015-09-18	2017-03-23	Redx Pharma Plc	Composés antibactériens et nouvelles utilisations de ceux-ci
TWI609870B (zh)	2016-02-12	2018-01-01	美國禮來大藥廠	Pde1抑制劑
TWI729109B (zh)	2016-04-12	2021-06-01	丹麥商Ｈ朗德貝克公司	作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JOP20170164A1 (ar)	2016-08-25	2019-01-30	Lilly Co Eli	مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
EP3529250B1 (fr)	2016-10-18	2023-12-06	H. Lundbeck A/S	Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1
US10905688B2 (en)	2016-10-28	2021-02-02	H. Lundbeck A/S	Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors
CA3041595A1 (fr)	2016-10-28	2018-05-03	H. Lundbeck A/S	Traitements combines comprenant l'administration d'imidazopyrazinones
EP3562828B1 (fr)	2016-12-28	2026-03-18	Dart Neuroscience LLC	Composés pyrazolopyrimidinone substitués en tant qu'inhibiteurs de pde2
MX390321B (es) *	2016-12-30	2025-03-20	Frequency Therapeutics Inc	Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
WO2018153887A1 (fr) *	2017-02-23	2018-08-30	Boehringer Ingelheim International Gmbh	Nouvelle utilisation médicale du composé iii
AR112457A1 (es)	2017-08-02	2019-10-30	Lilly Co Eli	Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
TW201920188A (zh)	2017-08-10	2019-06-01	美商美國禮來大藥廠	[1,2,4]三唑衍生物
WO2019104285A1 (fr)	2017-11-27	2019-05-31	Dart Neuroscience, Llc	Composés furanopyrimidine substitués utilisés en tant qu'inhibiteurs de pde1
JP7493454B2 (ja)	2018-04-13	2024-05-31	キャンサー・リサーチ・テクノロジー・リミテッド	Ｂｃｌ６阻害剤
GB2575490A (en) *	2018-07-12	2020-01-15	Recordati Ind Chimica E Farmaceutica Spa	P2X3 receptor antagonists
US12396992B2 (en)	2019-01-07	2025-08-26	Intra-Cellular Therapies, Inc.	Organic compounds
JP2022545802A (ja) *	2019-08-22	2022-10-31	イントラ－セルラー・セラピーズ・インコーポレイテッド	有機化合物
GB201914860D0 (en) *	2019-10-14	2019-11-27	Cancer Research Tech Ltd	Inhibitor compounds
CN112778311B (zh) *	2019-11-01	2024-06-04	上海翰森生物医药科技有限公司	含氮并环类衍生物抑制剂、其制备方法和应用
EP4389746A3 (fr) *	2022-12-21	2024-07-03	Recordati Industria Chimica E Farmaceutica SPA	Antagonistes des récepteurs p2x3
WO2025024543A1 (fr) *	2023-07-24	2025-01-30	Bpgbio, Inc.	Modulateurs d'ube2k tricycliques et leurs procédés d'utilisation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3046366A1 (de)	1980-12-09	1982-07-08	Bayer Ag, 5090 Leverkusen	Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
DE3146599A1 (de)	1981-11-25	1983-07-07	Basf Ag, 6700 Ludwigshafen	Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0181282A1 (fr)	1984-10-01	1986-05-14	Ciba-Geigy Ag	Composés de la triazolo-quinazoline
JPS62135475A (ja) *	1985-09-30	1987-06-18	チバ−ガイギ−　アクチエンゲゼルシヤフト	２−置換−ｅ−融合−〔１，２，４〕トリアゾロ−〔１，５−Ｃ〕ピリミジン
EP0217748B1 (fr)	1985-09-30	1991-02-06	Ciba-Geigy Ag	[1,2,4]Triazolo[1,5-c]pyrimidines condensées en e et substituées en 2, compositions pharmaceutiques et leur utilisation
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
FR2659329B1 (fr) *	1990-03-09	1994-06-03	Adir	Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US6110973A (en) *	1998-01-29	2000-08-29	Sepracor	Methods for treating obesity and weight gain using optically pure (-)-bupropion
ES2166270B1 (es) *	1999-07-27	2003-04-01	Almirall Prodesfarma Sa	Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
DE10012373A1 (de) *	2000-03-14	2001-09-20	Dresden Arzneimittel	Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
US7947731B2 (en)	2000-08-10	2011-05-24	Cold Spring Harbor Laboratory	Augmented cognitive training
US8153646B2 (en)	2000-08-10	2012-04-10	Dart Neuroscience (Cayman) Ltd.	Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7868015B2 (en)	2000-08-10	2011-01-11	Cold Spring Harbor Laboratory	Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
FR2897061B1 (fr) *	2006-02-03	2010-09-03	Sanofi Aventis	Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
EP2023729B1 (fr)	2006-06-06	2016-05-04	Intra-Cellular Therapies, Inc.	Composés organiques
EP2139333A4 (fr) *	2007-03-28	2010-11-10	Merck Sharp & Dohme	Dérivés de pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine substituée en tant que modulateurs du récepteur de cannabinoïde-1
US20090053140A1 (en)	2007-05-15	2009-02-26	Roderick Euan Milne Scott	METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA)
CN101809142A (zh) *	2007-09-26	2010-08-18	通用电气医疗集团生物科学生物方法公司	三维可用后即弃生物反应器
JP5068857B2 (ja)	2007-12-06	2012-11-07	武田薬品工業株式会社	有機化合物
JP2011507910A (ja)	2007-12-21	2011-03-10	ユニバーシティーオブロチェスター	真核生物の寿命を変更するための方法
JP5778582B2 (ja)	2008-12-06	2015-09-16	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
AU2009322905A1 (en) *	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
JP2012518685A (ja) *	2009-02-25	2012-08-16	イントラ−セルラー・セラピーズ・インコーポレイテッド	眼障害のためのｐｄｅ１阻害剤
WO2010132127A1 (fr)	2009-05-13	2010-11-18	Intra-Cellular Therapies, Inc.	Composés organiques
EP2576551A4 (fr)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	Composés organiques
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
EP2590657A4 (fr)	2010-05-31	2014-02-12	Intra Cellular Therapies Inc	Composés organiques
WO2011153136A1 (fr) *	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Composés organiques
WO2012171016A1 (fr)	2011-06-10	2012-12-13	Intra-Cellular Therapies, Inc.	Composés organiques
RU2659779C2 (ru)	2012-06-18	2018-07-04	Дарт Нейросайенс (Кайман) Лтд	Замещенные соединения тиофен- и фуран-конденсированного азолопиримидин-5-(6н)-она

2013
- 2013-06-18 RU RU2015100209A patent/RU2659779C2/ru active
- 2013-06-18 AU AU2013277298A patent/AU2013277298B2/en not_active Ceased
- 2013-06-18 WO PCT/US2013/046415 patent/WO2013192229A1/fr not_active Ceased
- 2013-06-18 CN CN201380043254.5A patent/CN104583217B/zh not_active Expired - Fee Related
- 2013-06-18 EP EP18213541.8A patent/EP3489238B8/fr active Active
- 2013-06-18 CA CA2877146A patent/CA2877146C/fr active Active
- 2013-06-18 MX MX2014015740A patent/MX357320B/es active IP Right Grant
- 2013-06-18 JP JP2015518523A patent/JP6129960B2/ja active Active
- 2013-06-18 SG SG11201408395WA patent/SG11201408395WA/en unknown
- 2013-06-18 DK DK18213541.8T patent/DK3489238T3/da active
- 2013-06-18 NZ NZ703950A patent/NZ703950A/en not_active IP Right Cessation
- 2013-06-18 MX MX2014015737A patent/MX359615B/es active IP Right Grant
- 2013-06-18 BR BR112014031731-3A patent/BR112014031731B1/pt active IP Right Grant
- 2013-06-18 SG SG10201703253XA patent/SG10201703253XA/en unknown
- 2013-06-18 US US14/408,942 patent/US9284335B2/en active Active
- 2013-06-18 IN IN334DEN2015 patent/IN2015DN00334A/en unknown
- 2013-06-18 EP EP13807708.6A patent/EP2861605B1/fr active Active
- 2013-06-18 JP JP2015518522A patent/JP6240180B2/ja active Active
- 2013-06-18 NZ NZ703949A patent/NZ703949A/en not_active IP Right Cessation
- 2013-06-18 EP EP13807565.0A patent/EP2861603B1/fr active Active
- 2013-06-18 BR BR112014031730-5A patent/BR112014031730B1/pt not_active IP Right Cessation
- 2013-06-18 CA CA2877149A patent/CA2877149C/fr active Active
- 2013-06-18 KR KR1020157001198A patent/KR102191816B1/ko active Active
- 2013-06-18 IN IN335DEN2015 patent/IN2015DN00335A/en unknown
- 2013-06-18 RU RU2015100213A patent/RU2653054C2/ru active
- 2013-06-18 US US13/920,974 patent/US9175010B2/en active Active
- 2013-06-18 ES ES13807565T patent/ES2715325T3/es active Active
- 2013-06-18 SG SG11201408397SA patent/SG11201408397SA/en unknown
- 2013-06-18 CN CN201380043291.6A patent/CN104583213B/zh not_active Expired - Fee Related
- 2013-06-18 WO PCT/US2013/046403 patent/WO2013192225A1/fr not_active Ceased
- 2013-06-18 DK DK13807565.0T patent/DK2861603T3/en active
- 2013-06-18 AU AU2013277294A patent/AU2013277294C1/en not_active Ceased
- 2013-06-18 US US14/408,927 patent/US9499562B2/en active Active
- 2013-06-18 ES ES18213541T patent/ES2904267T3/es active Active
- 2013-06-18 KR KR1020157001117A patent/KR102087756B1/ko active Active
2014
- 2014-12-14 IL IL236233A patent/IL236233A/en active IP Right Grant
- 2014-12-14 IL IL236232A patent/IL236232A/en active IP Right Grant
2015
- 2015-09-14 US US14/853,856 patent/US9533996B2/en active Active
2016
- 2016-11-17 US US15/354,804 patent/US10092575B2/en active Active
- 2016-12-29 US US15/394,058 patent/US10105367B2/en active Active
2017
- 2017-12-07 AU AU2017272245A patent/AU2017272245B2/en active Active
2018
- 2018-10-18 US US16/164,726 patent/US10376514B2/en active Active

Also Published As

Publication number	Publication date
BR112014031731B1 (pt)	2022-12-06
US20170209459A1 (en)	2017-07-27
EP2861605A4 (fr)	2016-01-13
AU2013277294B2 (en)	2017-04-13
BR112014031731A2 (pt)	2017-06-27
BR112014031730A2 (pt)	2017-06-27
NZ703950A (en)	2016-10-28
KR20150063028A (ko)	2015-06-08
US20190046535A1 (en)	2019-02-14
JP2015526394A (ja)	2015-09-10
RU2653054C2 (ru)	2018-05-07
US9284335B2 (en)	2016-03-15
CN104583217B (zh)	2017-11-17
SG11201408397SA (en)	2015-01-29
ES2904267T3 (es)	2022-04-04
KR20150063030A (ko)	2015-06-08
US20170182052A1 (en)	2017-06-29
EP2861605B1 (fr)	2017-05-03
EP3489238B8 (fr)	2022-02-16
IN2015DN00335A (fr)	2015-06-12
WO2013192225A1 (fr)	2013-12-27
RU2015100209A (ru)	2016-08-10
CN104583213B (zh)	2018-10-26
CN104583217A (zh)	2015-04-29
JP6129960B2 (ja)	2017-05-17
AU2017272245B2 (en)	2019-08-29
RU2659779C2 (ru)	2018-07-04
CN104583213A (zh)	2015-04-29
EP3489238B1 (fr)	2021-10-13
RU2015100213A (ru)	2016-08-10
EP2861603A4 (fr)	2015-11-11
AU2017272245A1 (en)	2018-01-04
JP2015526395A (ja)	2015-09-10
US9533996B2 (en)	2017-01-03
US20160075719A1 (en)	2016-03-17
CA2877149A1 (fr)	2013-12-27
KR102087756B1 (ko)	2020-03-12
IL236233A0 (en)	2015-02-01
AU2013277294C1 (en)	2018-02-08
MX359615B (es)	2018-10-03
US20150158885A1 (en)	2015-06-11
US9175010B2 (en)	2015-11-03
WO2013192229A1 (fr)	2013-12-27
US10105367B2 (en)	2018-10-23
CA2877146A1 (fr)	2013-12-27
EP2861605A1 (fr)	2015-04-22
EP2861603B1 (fr)	2018-12-19
IL236233A (en)	2016-10-31
US20130338139A1 (en)	2013-12-19
EP2861603A1 (fr)	2015-04-22
IL236232A0 (en)	2015-02-01
DK3489238T3 (da)	2022-01-10
HK1208024A1 (en)	2016-02-19
NZ703949A (en)	2016-10-28
US9499562B2 (en)	2016-11-22
AU2013277298A1 (en)	2015-02-05
KR102191816B1 (ko)	2020-12-17
CA2877149C (fr)	2021-01-19
CA2877146C (fr)	2020-10-20
WO2013192229A8 (fr)	2015-09-03
BR112014031730B1 (pt)	2023-05-16
DK2861603T3 (en)	2019-03-04
US10092575B2 (en)	2018-10-09
US20160031901A1 (en)	2016-02-04
MX2014015740A (es)	2015-11-06
MX357320B (es)	2018-07-04
SG10201703253XA (en)	2017-06-29
US10376514B2 (en)	2019-08-13
IL236232A (en)	2016-10-31
HK1208023A1 (en)	2016-02-19
ES2715325T3 (es)	2019-06-03
MX2014015737A (es)	2015-09-16
SG11201408395WA (en)	2015-01-29
JP6240180B2 (ja)	2017-11-29
EP3489238A1 (fr)	2019-05-29
AU2013277294A1 (en)	2015-02-05
AU2013277298B2 (en)	2017-09-07

Publication	Publication Date	Title
IN2015DN00334A (fr)	2015-06-12
MX366318B (es)	2019-07-05	Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
IL239355A0 (en)	2015-07-30	Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
PH12015500525A1 (en)	2015-05-04	Formulations of enzalutamide
EP2925775A4 (fr)	2016-07-13	Compositions et méthodes de traitement de troubles et maladies métaboliques
EA201290909A1 (ru)	2013-05-30	Химические соединения
IN2015DN00372A (fr)	2015-06-12
PL2925757T3 (pl)	2018-06-29	Związki i kompozycje do leczenia chorób pasożytniczych
MX353299B (es)	2018-01-08	Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
BR112014026326A2 (pt)	2017-06-27	composição para tratamento de distúrbios metabólicos
IL234606A0 (en)	2014-11-30	Innovative methods and compounds for the treatment of diseases
CR20140528A (es)	2015-01-12	Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de Bace1
PL2892556T3 (pl)	2019-11-29	Kompozycje i sposoby odnoszące się do leczenia chorób
IN2015DN00345A (fr)	2015-06-12
SG11201404649UA (en)	2014-09-26	Novel compounds for the treatment of dyslipidemia and related diseases
MX2015008454A (es)	2016-05-16	Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
SG11201504779YA (en)	2015-07-30	Methods and compositions relating to treatment of cancer
MX2015005312A (es)	2015-11-16	Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
EA033160B1 (ru)	2019-09-30	Соединения для лечения заболеваний, связанных с ишемией-реперфузией